TFDA

TLC Biopharmaceuticals reports results of phase I/II tlc599 osteoarthritis trial

Wednesday, January 11, 2017

TLC has reported top-line results from the phase I/II trial of TLC599 for sustained pain management in patients with osteoarthritis of the knee. The trial demonstrated a positive safety profile for a single intra-articular injection of either a 6mg or 12mg dose of TLC599. In addition, the trial demonstrated a trend of sustained, clinically meaningful decrease from baseline through week 12 in several widely-used assessments of pain. These results support the potential for TLC599 to address the problem of a limited duration of action for steroid therapy in patients with osteoarthritis. 

[Read More]